Retraction: Potent Anti-Proliferative, Pro-Apoptotic Activity of the Maytenus Royleanus Extract against Prostate Cancer Cells: Evidence in In-Vitro and In-Vivo Models (PLoS ONE (2015) 10: 3 (e0119859) DOI: 10.1371/journal.pone.0119859);Potent anti-proliferative, pro-apoptotic activity of the Maytenus Royleanus extract against prostate cancer cells: Evidence in in- vitro and in-vivo models

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Shabbir, Maria ^a,b   Syed, Deeba N ^a   Lall, Rahul K ^a   Khan, Muhammad Rashid ^b   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CAFFEIC ACID; CASPASE 3; FLAVONOID; MAYTENUS ROYLEANUS EXTRACT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; QUERCITRIN; TANNIN DERIVATIVE; TRITERPENOID; UNCLASSIFIED DRUG; CASPASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELASTRACEAE; CELL VIABILITY; CHEMICAL COMPOSITION; CONTROLLED STUDY; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAYTENUS ROYLEANUS; MOUSE; NONHUMAN; PLANT LEAF; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; MAYTENUS; METABOLISM; MITOCHONDRION; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALIA; MAYTENUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; IN VITRO TECHNIQUES; MALE; MAYTENUS; MICE; MICE, NUDE; MITOCHONDRIA; PLANT EXTRACTS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925781494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0297383     Document Type: Erratum

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012; 62 (1):10-29. Epub 2012/01/13.
2. wwwcancerorg/
3. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Seminars in oncology. 2003; 30(5):709-16. Epub 2003/10/23. PMID: 14571418
4. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature genetics. 1995; 9 (4):401-6. Epub 1995/04/01. PMID: 7795646
5. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer research. 1998; 58(24):5718-24. Epub 1998/12/29. PMID: 9865729
6. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32 (49):5501-11. Epub 2013/06/12. doi: 10.1038/onc.2013.206 PMID: 23752182
7. Gottlieb B, Beitel LK, Trifiro MA. Variable expressivity and mutation databases: The androgen receptor gene mutations database. Human mutation. 2001; 17(5):382-8. Epub 2001/04/24. PMID: 11317353
8. Chen FZ, Zhao XK. Prostate cancer: current treatment and prevention strategies. Iranian Red Crescent medical journal. 2013; 15(4):279-84. Epub 2013/10/02. doi: 10.5812/ircmj.6499 PMID: 24082997
9. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert opinion on investigational drugs. 2009; 18(7):1001-11. Epub 2009/06/25. doi: 10.1517/13543780902997928 PMID: 19548854
10. Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. The Journal of steroid biochemistry and molecular biology. 2014; 140:116-32. Epub 2014/01/01. doi: 10.1016/j.jsbmb.2013.12.010 PMID: 24373791
11. Mariani S, Lionetto L, Cavallari M, Tubaro A, Rasio D, De Nunzio C, et al. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. International journal of molecular sciences. 2014; 15(1):1433-40. Epub 2014/01/24. doi: 10.3390/ijms15011433 PMID: 24451130
12. Kenfield SA, DuPre N, Richman EL, Stampfer MJ, Chan JM, Giovannucci EL. Mediterranean diet and prostate cancer risk and mortality in the health professionals follow-up study. European urology. 2014; 65(5):887-94. Epub 2013/08/22. doi: 10.1016/j.eururo.2013.08.009 PMID: 23962747
13. Schaneberg BT, Green DK, Sneden AT. Dihydroagarofuran sesquiterpene alkaloids from Maytenus putterlickoides. Journal of natural products. 2001; 64(5):624-6. Epub 2001/05/26. PMID: 11374957
14. Perestelo NR, Jimenez IA, Tokuda H, Hayashi H, Bazzocchi IL. Sesquiterpenes from Maytenus jelskii as potential cancer chemopreventive agents. Journal of natural products. 2010; 73(2):127-32. Epub 2010/02/12. doi: 10.1021/np900476a PMID: 20146433
15. Shabbir M, Khan MR, Saeed N. Assessment of phytochemicals, antioxidant, anti-lipid peroxidation and anti-hemolytic activity of extract and various fractions of Maytenus royleanus leaves. BMC complementary and alternative medicine. 2013; 13:143. Epub 2013/06/27. doi: 10.1186/1472-6882-13-143 PMID: 23800043
16. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis: an international journal on programmed cell death. 2002; 7(4):321-8. Epub 2002/07/09. PMID: 12101391
17. Lamb DJ, Weigel NL, Marcelli M. Androgen receptors and their biology. Vitamins and hormones. 2001; 62:199-230. Epub 2001/05/11. PMID: 11345899
18. Tsao CK, Cutting E, Martin J, Oh WK. The role of cabazitaxel in the treatment of metastatic castrationresistant prostate cancer. Therapeutic advances in urology. 2014; 6(3):97-104. Epub 2014/06/03. doi: 10.1177/1756287214528557 PMID: 24883107
19. Guo WD, Hsing AW, Li JY, Chen JS, Chow WH, Blot WJ. Correlation of cervical cancer mortality with reproductive and dietary factors, and serum markers in China. International journal of epidemiology. 1994; 23(6):1127-32. Epub 1994/12/01. PMID: 7721512
20. Ekstrom AM, Serafini M, Nyren O, Hansson LE, Ye W, Wolk A. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. International journal of cancer Journal international du cancer. 2000; 87(1):133-40. Epub 2000/06/22. PMID: 10861464
21. Kellen E, Zeegers M, Paulussen A, Van Dongen M, Buntinx F. Fruit consumption reduces the effect of smoking on bladder cancer risk. The Belgian case control study on bladder cancer. International journal of cancer Journal international du cancer. 2006; 118(10):2572-8. Epub 2005/12/29. PMID: 16380991
22. Liu RH. Dietary bioactive compounds and their health implications. Journal of food science. 2013; 78 Suppl 1:A18-25. Epub 2013/06/29. doi: 10.1111/1750-3841.12101 PMID: 23789932
23. Syed DN, Suh Y, Afaq F, Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer letters. 2008; 265(2):167-76. Epub 2008/04/09. doi: 10.1016/j.canlet.2008.02.050 PMID: 18395333
24. Syed DN, Chamcheu JC, Adhami VM, Mukhtar H. Pomegranate extracts and cancer prevention: molecular and cellular activities. Anti-cancer agents in medicinal chemistry. 2013; 13(8):1149-61. Epub 2012/10/26. PMID: 23094914
25. Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, et al. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Investigational new drugs. 2005; 23(1):11-20. Epub 2004/11/06. PMID: 15528976
26. Seeram NP, Adams LS, Hardy ML, Heber D. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. Journal of agricultural and food chemistry. 2004; 52(9):2512-7. Epub 2004/04/29. PMID: 15113149
27. Viladomiu M, Hontecillas R, Lu P, Bassaganya-Riera J. Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evidence-based complementary and alternative medicine: eCAM. 2013; 2013:789764. Epub 2013/06/06. doi: 10.1155/2013/789764 PMID: 23737845
28. Kim J. Protective effects of Asian dietary items on cancers-soy and ginseng. Asian Pacific journal of cancer prevention: APJCP. 2008; 9(4):543-8. Epub 2009/03/05. PMID: 19256735
29. Cai X, Fang Z, Dou J, Yu A, Zhai G. Bioavailability of quercetin: problems and promises. Current medicinal chemistry. 2013; 20(20):2572-82. Epub 2013/03/22. PMID: 23514412
30. Russo GL, Russo M, Spagnuolo C, Tedesco I, Bilotto S, Iannitti R, et al. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer treatment and research. 2014; 159:185-205. Epub 2013/10/12. doi: 10.1007/978-3-642-38007-5-11 PMID: 24114481
31. Touaibia M, Jean-Francois J, Doiron J. Caffeic Acid, a versatile pharmacophore: an overview. Mini reviews in medicinal chemistry. 2011; 11(8):695-713. Epub 2011/06/18. PMID: 21679136
32. Baillon L, Basler K. Reflections on cell competition. Seminars in cell & developmental biology. 2014; 32C:137-44. Epub 2014/05/09.
33. Sanchez I, Dynlacht BD. New insights into cyclins, CDKs, and cell cycle control. Seminars in cell & developmental biology. 2005; 16(3):311-21. Epub 2005/04/21.
34. Sola S, Morgado AL, Rodrigues CM. Death receptors and mitochondria: two prime triggers of neural apoptosis and differentiation. Biochimica et biophysica acta. 2013; 1830(1):2160-6. Epub 2012/10/09. doi: 10.1016/j.bbagen.2012.09.021 PMID: 23041071
35. Santamaria D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Frontiers in bioscience: a journal and virtual library. 2006; 11:1164-88. Epub 2005/09/09. PMID: 16146805
36. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Molecular cancer therapeutics. 2003; 2(6):573-80. Epub 2003/06/19. PMID: 12813137
37. Khan KH, Blanco-Codesido M, Molife LR. Cancer therapeutics: Targeting the apoptotic pathway. Critical reviews in oncology/hematology. 2014; 90(3):200-19. Epub 2014/02/11. doi: 10.1016/j.critrevonc.2013.12.012 PMID: 24507955
38. Farooqi AA, Hou MF, Chen CC, Wang CL, Chang HW. Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. Cancer cell international. 2014; 14:34. Epub 2014/04/18. doi: 10.1186/1475-2867-14-34 PMID: 24739220
39. Mellado B, Codony J, Ribal MJ, Visa L, Gascon P. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2009; 11(1):5-10. Epub 2009/01/22.
40. Sharifi N. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. Anti-cancer agents in medicinal chemistry. 2009; 9(10):1046-51. Epub 2009/09/02. PMID: 19719456
41. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. The Journal of steroid biochemistry and molecular biology. 2005; 96(3-4):251-8. Epub 2005/06/29. PMID: 16168635
42. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer metastasis reviews. 2001; 20(3-4):207-23. Epub 2002/06/ 28. PMID: 12085968
43. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nature medicine. 2004; 10(1):33-9. Epub 2004/01/02. PMID: 14702632